Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 393 (CSE: $EASY.C), (TSXV: $N.V) (OTC: $NXTTF), (TSXV: $NRTH.V)
Delta, Kelowna, BC, April 1, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/04011EASY-N-NXTTF-NRTH.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as insights
from thought leaders and experts.
In
today’s podcast we are looking at a few public announcements.
Neuraxpharm, a
leading European specialty pharmaceutical company, together with Panaxia Labs Israel (TASE:
PNAX), Israel's largest medical cannabis manufacturer, today
announced it is starting to market medical cannabis products,
becoming the first European pharmaceutical company to include medical cannabis
products in its portfolio. Neuraxpharm, which specializes in pharmaceutical
products for the central nervous system (CNS), chose Panaxia Labs Israel,
Israel's largest medical cannabis manufacturer, as its partner in a business
collaboration for the manufacture, commercialization and distribution of
advanced medical cannabis products in Germany, Europe's largest and
fastest-growing medical cannabis market.
The breakthrough
agreement inked by the two companies positions them as dominant players in the
international cannabis market. The agreement is expected to cover more markets
in the future. To date, collaborations between large pharmaceutical and medical
cannabis companies were limited to research and development partnerships or
local-scale distribution. The establishment of the business collaboration
reflects Neuraxpharm's and Panaxia's strategy to become a European leader in
the commercialization of medical cannabis products.
Currently, a
complex patchwork and different regulatory approaches for cannabis use are
found across the European countries. While the sector is still in its early
stages, market possibilities are expected to increase strongly with the growing
acceptance of medical cannabis in more countries.
With its direct
presence in now 12 European countries and annual revenues of around EUR 480
million, Neuraxpharm is a leading European CNS Specialist. Neuraxpharm covers
over 80% of the European CNS drug market with its pharmaceutical products with
more than 130 different CNS active ingredients.
With over 60,000
patients treated with medical cannabis (out of a total population of 82.8
million), Germany is the largest medical cannabis market outside the USA. The
average cannabis expenditure per patient in Germany is EUR500 per month. The
market is backed by regulatory support, concurrently with strict quality
standards and increasing demand for advanced administration methods. With the
consistent increase in the number of patients treated with medical cannabis,
the market is expected to account for 1-2% of Germany's population in four
years. Products are prepared and sold prescription only by specially certified
pharmacies.
Initial sales in
Germany of the Panaxia / Neuraxpharm medical cannabis products are expected upon
the receipt of the regulatory approval later in 2020.
SpeakEasy Cannabis
Club Ltd. (CSE:
EASY), a holder of a federal licence to cultivate, process
and sell cannabis under the Cannabis Act, announced that it
has signed a non-binding letter of intent with Christina Lake Cannabis Corp.
The
LOI contemplates that CLC will contract SpeakEasy to process and sell cannabis
biomass and cannabis flower produced at their CLC production facility and
SpeakEasy intends to provide, upon receipt of the appropriate licences,
processing of biomass and flower, sales and distribution of the flowers and
work jointly with CLC to develop and produce white label, value added products
made from CLC input material.
Contract
processing for CLC will make use of SpeakEasy's process facility to become an
additional revenue stream. The additional material is expected to aid in
SpeakEasy's ability to keep up to expected domestic and international markets.
Climatic
region, genetics and growing techniques of CLC, being similar to SpeakEasy's
methods, allows for easy cooperation and sharing of supplies, equipment and
technology between the two companies. Growers on both farms have vast
experience, therefore it is expected that the finished product will be
comparable and will market well together. Founder Marc Geen states, "I'm
thrilled to be working with the team from Christina Lake Cannabis, we've known
each other for years and I couldn't be happier to have our two families
cooperating together."
SpeakEasy
anticipates that it will have a strong effect on the market with the cost of
its flower produced outdoors being comparatively lower than the industry
average. Having additional supply of extremely competitively priced material
will allow us to enter more supply agreements with Province's across Canada.
SpeakEasy
is working with and supporting local growers and producers both large and small
here in BC with a goal of promoting "BC Bud" as a globally recognized
brand. Founder, Marc Geen states, "Working with other like-minded growers
towards a common goal is extremely exciting, it happens in all other forms of
farming for very good reason. We have so many advantages growing in BC, working
with fellow farmers can compound those advantages."
Namaste
Technologies Inc. (TSXV:
N) (OTC:
NXTTF), a leading online platform for cannabis products,
accessories, and responsible education, today
provided an update with respect to the impact from the COVID-19
virus outbreak on its current operations.
On
March 23, 2020 the Ontario government announced non-essential services must
close their doors due to the COVID-19 pandemic, however certain sectors of the
economy including liquor and cannabis retail and wholesale operations have been
deemed essential services and are permitted to operate. Other provincial
governments have followed Ontario's lead and many online and retail cannabis
stores remain open across Canada. Namaste's wholly owned subsidiary, CannMart
Inc. ("CannMart") plays an important role within the Canadian
cannabis supply chain and is committed to remain open to serve its online
patients and B2B customers including provincial government stores. Where
possible employees are working from home and others are adhering to strict operating
procedures to safeguard the health and safety of staff to ensure operations
remain unaffected. To date, there have been no known cases of COVID-19 at any
of Namaste offices or facilities and there have been no operational
disruptions.
"In
these extraordinary times, our thoughts go out to those working the frontlines
and those who have been touched by the coronavirus," said Meni Morim, CEO
of Namaste Technologies. "The health and safety of our people, patients
and customers, business partners, investors and their communities are our top
priority. We will continue to monitor the progress of COVID-19 developments and
will act accordingly for the health and safety of all stakeholders."
Namaste
also announced that its continuing effort to strengthen its business model with
the addition of Adastra Labs to the Namaste and CannMart family. CannMart Labs
Inc. has entered into an agreement with Adastra
Labs Holdings Ltd. (CSE:
XTRX) to supply cannabis extract and concentrate products.
Adastra is a provider of same-site Health Canada licensed cannabis extraction
and analytical testing services. The agreement provides for supply of cannabis
extract and concentrates for Namaste's family of products available through
CannMart.com and Namaste's network of government cannabis stores. Under the
terms of the agreement, Adastra will supply standard processing services to
CannMart Labs for cannabis extract and concentrate products over a period of 12
months expected to begin on May 1st, 2020.
According
to a recent article in the Marijuana Business Daily industry sources say
cannabis stores in Ontario and Alberta have reported unprecedented demand due
in part to the COVID-19 outbreak. Namaste is committed to managing the recent
surge in demand by keeping the supply lines open to its patients and customers
while continuing to focus on employee and customer health. The Company has been
successful at adding additional cannabis brands and products to CannMart's
product line. Adastra Labs is a part of Namaste's increase in focus on
profitable business relationships as it navigates the new realities facing the
cannabis industry.
As
previously announced in January, CannMart submitted notification for several
new product SKUs including edible cannabis products, which are being
manufactured by Choklat Inc, a company that Namaste holds a 49% equity interest
in. These products are to be formulated, developed and packaged to meet the
regulatory requirements as set out by Health Canada. While the Company expected
to make these new products available in March, delays in packaging materials
has caused the Company to defer its delivery schedule at this time.
Fume Labs, and 48North Cannabis Corp. (TSXV:
NRTH) announced
today that it signed a supply agreement with PAX Labs
(Canada) Inc.
Under
the terms of the agreement, Fume Labs will develop cannabis oil pods for the
PAX Era.
The
PAX Era, an award-winning vaporizer system for cannabis concentrates, will
provide consumers with a superior cannabis experience, delivering quality,
control and predictability to each session. PAX is a market leader in
vaporization technology, with nearly 1.5 million Era devices sold and an
established reputation as the best-selling pen-and-pod system in the United
States.
The
agreement between PAX Labs – an industry-leading brand, well-known for premium
quality and consistency – and Fume Labs is a testament to Fume Labs'
operational expertise in the production of cannabis products, specializing in
concentrate extraction and refining, formulation and filling, and packaging and
distribution.
At
launch, Fume Labs will manufacture two cannabis oil pods for the PAX Era:
- 48North branded pod: 48North's recognizable, market-leading,
and beloved brand; single stain, ultra-refined and purified cartridge
filled with cannabis from 48North's indoor, craft facility delshen
- Trail Mix branded pod: an accessibly priced cartridge filled with
cannabis from 48North's outdoor, natural production facility, Good:Farm
Importantly,
Fume Labs' Chief Science Officer, Talaal Rshaidat has significant experience
filling
PAX Era pods in the United States, most recently with Liberty Health Sciences,
where he was responsible for extraction and product development. Talaal's
experience is invaluable to Fume Labs and well positions the strategic
partnership to successfully deliver on this agreement with Pax Labs.
In
the near term, Fume Labs looks forward to announcing additional partnerships,
with other Licensed Producers and cannabis brands.
Fume
Labs, the cannabis-focused manufacturing and extraction entity operates out of
48North's
fully-licensed processing and propagation facility "Good:House,"
located in Brantford, ON.
48North
is the party responsible for manufacturing, packaging, marketing, and
promoting, and selling products from Fume Labs under the authority of its
cannabis licenses.
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com
website and this podcast is not an endorsement to buy products or services or
securities. Investors are reminded all investment involves risk and possible
loss of investment
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and followers.
Contact management and IR of each company directly regarding specific
questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Contact Investorideas.com
800
665 0411
